^
Association details:
| Biomarker: | ASNS deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | IPN60090 (Glutaminase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
Published date:
05/19/2021
Excerpt:
SD ≥6 months +/- tumor regression were seen in pts with advanced ASNS-loss ovarian cancer (n=2), PD-1/L1-exposed melanoma (n=2) and NF1 mutant leiomyosarcoma (n=1)….IACS-6274 was well tolerated at biologically active doses with good human PK, significant PD target modulation and preliminary antitumor activity observed.
DOI:
10.1200/JCO.2021.39.15_suppl.3001
Trial ID:
